⌕
Kiniksa Pharmaceuticals International · KNSA · Nasdaq
Tenet 55 · Mixed
Compare
$95.11+0.93%At closeTenet 55 · Mixed
$95.11+0.88 (+0.93%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Kiniksa Pharmaceuticals International (KNSA) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (27 new · 43 increased · 26 reduced · 4 closed · 14 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 114 filers, Sep 30, 2026
# 13F FUNDS
114
13F VALUE
$392.6M
5.3M shares
Not reported in the company's filings for this period.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Nov 4, 2026Patel Sanj KCHAIRMAN & CEOAcquired · Option exercise145,763$17.92↗
Nov 4, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale1,460$92.35↗
Nov 4, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale11,335$93.54↗
Nov 4, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale81,742$94.20↗
Nov 4, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale29,845$95.48↗
Nov 4, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale26,918$96.05↗
Nov 4, 2026Patel Sanj KCHAIRMAN & CEODisposed · Option exercise145,763Share Option—↗
Nov 3, 2026Patel Sanj KCHAIRMAN & CEOAcquired · Option exercise89,089$8.83↗
Nov 3, 2026Patel Sanj KCHAIRMAN & CEOAcquired · Option exercise41,237$17.92↗
Nov 3, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale1,214$90.77↗
Nov 3, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale68,664$92.70↗
Nov 3, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale145,708$93.53↗
Nov 3, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale4,584$94.25↗
Nov 3, 2026Patel Sanj KCHAIRMAN & CEODisposed · Option exercise89,089Share Option—↗
Nov 3, 2026Patel Sanj KCHAIRMAN & CEODisposed · Option exercise41,237Share Option—↗
Nov 2, 2026Patel Sanj KCHAIRMAN & CEOAcquired · Option exercise53,381$8.83↗
Nov 2, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale38,364$91.03↗
Nov 2, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale24,188$91.83↗
Nov 2, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale26,781$93.06↗
Nov 2, 2026Patel Sanj KCHAIRMAN & CEODisposed · Open-market sale100$93.97↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International was held by 114 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.